Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Gastroenterology. 2018 Aug 23;155(6):1985–1998.e5. doi: 10.1053/j.gastro.2018.08.028

Figure 5: Metavert significantly increases survival of KPC mice and completely prevents metastasis.

Figure 5:

KPC mice were intraperitoneally injected starting from the age of 2 months with 5mg/Kg of metavert 3 times per week (A). (B) Survival data of KPC mice. (C) Tumor weight at the death of mice. (D) Liver metastasis and quantification of percentage of mice with metastasis. (E) H&E staining of pancreatic tissue from control mice (a, b) and metavert-treated mice (c, d). (F) CK19 staining of pancreatic and liver tissues from control mice (a, b) and metavert-treated mice (c, d). (G) S100P staining of pancreatic and liver tissues from control mice (a, b) and metavert-treated mice (c, d). (H) Sirius Red/Collagen staining of KPC mice pancreas with quantification. (I) M2 macrophage staining with F4/80 and Arginase1 antibodies and quantification. (J) Survival data of KPC mice intraperitoneally injected with Gemcitabine (10mg/Kg) once a week and metavert (5mg/Kg) 3 times per week. *, p < 0.05 versus control.